Summary
Moderna's stock surged after the company and Merck announced "landmark moment" study results for their melanoma vaccine trial, showing significant progress in treating skin cancer.
Moderna Stock Jumps as Melanoma Vaccine Trial Shows 'Landmark Moment' Results
HyperFast News
Related news
Moderna Cancer Vaccine Offers Hope, Urging Faster Personalized Therapy Development
20 Sept 2026, 3:01 am · News
Moderna's Cancer Vaccine Cuts Melanoma Recurrence Risk in Early Trial
20 Sept 2026, 3:01 am · News
Moderna, Merck Cancer Vaccine Achieves Breakthrough in Final-Stage Melanoma Trial
20 Sept 2026, 3:01 am · News
